Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8471-8476

  Raskatov, Jevgenij A ^a   Szablowski, Jerzy O ^a   Dervan, Peter B ^a  

^a California Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; IMIDAZOLE DERIVATIVE; POLYAMIDE; PYRROLE DERIVATIVE; COLLAGEN; DRUG COMBINATION; LAMININ; MATRIGEL; NYLON; PROTEOGLYCAN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR CELL LINE; CONTROLLED STUDY; DNA SEQUENCE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY PARENCHYMA; LNCAP CELL LINE; LUNG CANCER CELL LINE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; TISSUE DISTRIBUTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; DRUG COMBINATION; DRUG SCREENING; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; HUMANS; IMIDAZOLES; LAMININ; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; NYLONS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; PYRROLES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908375100     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500964c     Document Type: Article

References (37)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014 Ca-Cancer J. Clin. 2014, 64, 9-29
2. Ries, L. A. G. SEER Cancer Statistics Review, 1975-2005; U.S. National Institutes of Health, National Cancer Institute: Bethesda, MD, 2008
3. Hoyert, D. L.; Xu, J. Deaths: Preliminary Data for 2011 Natl. Vital Stat. Rep. 2012, 61, 1-52
4. Patel, J. D. Clinical Cancer Advances 2013: Annual Report on Progress against Cancer from the American Society of Clinical Oncology J. Clin. Oncol. 2014, 32, 129-160
5. Huitink, J. M.; Teoh, W. H. L. Current cancer therapies-a guide for perioperative physicians Best Pract. Res., Clin. Anaesthesiol. 2013, 27, 481-492
6. Peer, D.; Karp, J. M.; Hong, S.; FaroKhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760
7. Denny, W. A. Prodrug strategies in cancer therapy Eur. J. Med. Chem. 2001, 36, 577-595
8. Druker, B. J. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 2001, 344, 1031-1037
9. Baselga, J.; Arteaga, C. L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J. Clin. Oncol. 2005, 23, 2445-2459
10. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal Cancer Sci. 2003, 94, 15-21
11. Pai, V. B.; Nahata, M. C. Cardiotoxicity of chemotherapeutic agents-incidence, treatment and prevention Drug Saf. 2000, 22, 263-302
12. Verstappen, C. C. P.; Heimans, J. J.; Hoekman, K.; Postma, T. J. Neurotoxic complications of chemotherapy in patients with cancer-clinical signs and optimal management Drugs 2003, 63, 1549-1563
13. Aapro, M. S. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur. J. Cancer 2006, 42, 2433-2453
14. Dervan, P. B.; Edelson, B. S. Recognition of the DNA minor groove by pyrrole-imidazole polyamides Curr. Opin. Struct. Biol. 2003, 13, 284-299
15. Hsu, C. F. Completion of a programmable DNA-binding small molecule library Tetrahedron 2007, 63, 6146-6151
16. Kielkopf, C. L.; White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P. B.; Rees, D. C. A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA Science 1998, 282, 111-115
17. White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P. B. Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands Nature 1998, 391, 468-471
18. Edelson, B. S.; Best, T. P.; Olenyuk, B.; Nickols, N. G.; Doss, R. M.; Foister, S.; Heckel, A.; Dervan, P. B. Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates Nucleic Acids Res. 2004, 32, 2802-2818
19. Nickols, N. G.; Jacobs, C. S.; Farkas, M. E.; Dervan, P. B. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface ACS Chem. Biol. 2007, 2, 561-571
20. Nickols, N. G.; Dervan, P. B. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 10418-10423
21. Muzikar, K. A.; Nickols, N. G.; Dervan, P. B. Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16598-16603
22. Raskatov, J. A.; Meier, J. L.; Puckett, J. W.; Yang, F. T.; Ramakrishnan, P.; Dervan, P. B. Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 1023-1028
23. Yang, F.; Nickols, N. G.; Li, B. C.; Marinov, G. K.; Said, J. W.; Dervan, P. B. Antitumor activity of a pyrrole-imidazole polyamide Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 1863-1868
24. Yang, F.; Nickols, N. G.; Li, B. C.; Szablowski, J. O.; Hamilton, S. R.; Meier, J. L.; Wang, C.-M.; Dervan, P. B. Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit J. Med. Chem. 2013, 56, 7449-7457
25. Raskatov, J. A.; Hargrove, A. E.; So, A. Y.; Dervan, P. B. Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear J. Am. Chem. Soc. 2012, 134, 7995-7999
26. Synold, T. W.; Xi, B. X.; Wu, J.; Yen, Y.; Li, B. C.; Yang, F.; Phillips, J. W.; Nickols, N. G.; Dervan, P. B. Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice Cancer Chemother. Pharmacol. 2012, 70, 617-625
27. Raskatov, J. A.; Nickols, N. G.; Hargrove, A. E.; Marinov, G. K.; Wold, B.; Dervan, P. B. Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 16041-16045
28. Nickols, N. G.; Szablowski, J. O.; Hargrove, A. E.; Li, B. C.; Raskatov, J. A.; Dervan, P. B. Activity of a Py-Im polyamide targeted to the estrogen response element Mol. Cancer Ther. 2013, 12, 675-684
29. Raskatov, J. A.; Puckett, J. W.; Dervan, P. B. A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor Bioorg. Med. Chem. 2014, 22, 4371-4375
30. Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved Cancer Biol. Ther. 2003, 2, 133-138
31. Frese, K. K.; Tuveson, D. A. Maximizing mouse cancer models Nat. Rev. Cancer 2007, 7, 645-658
32. Becher, O. J.; Holland, E. C. Genetically engineered models have advantages over xenografts for preclinical studies Cancer Res. 2006, 66, 3355-3358
33. Sausville, E. A.; Burger, A. M. Contributions of human tumor xenografts to anticancer drug development Cancer Res. 2006, 66, 3351-3354
34. Szablowski, J. O.; Raskatov, J. A.; Dervan, P. B. Unpublished data.
35. Bao, L.; Matsumura, Y.; Baban, D.; Sun, Y.; Tarin, D. Effects of inoculation site and Matrigel on growth and metastasis of human breast-cancer cells Br. J. Cancer 1994, 70, 228-232
36. Shuhendler, A. J.; Prasad, P.; Cai, P.; Hui, K. K. W.; Henderson, J. T.; Rauth, A. M.; Wu, X. Y. Matrigel alters the pathophysiology of orthotopic human breast adenocarcinoma xenografts with implications for nanomedicine evaluation Nanomed.-Nanotechnol. Biol. Med. 2013, 9, 795-805
37. Fridman, R.; Kibbey, M. C.; Royce, L. S.; Zain, M.; Sweeney, T. M.; Jicha, D. L.; Yannelli, J. R.; Martin, G. R.; Kleinman, H. K. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel J. Natl. Cancer Inst. 1991, 83, 769-774